Biotropics Malaysia, a developer and provider of functional ingredients for the nutraceutical market, has published the data from a study that spotlights the antiviral properties of the traditional herb Eurycoma longifolia.
E. longifolia, which is sometimes called longjack or Tongkat Ali, is a plant traditionally used in south-east Asia to enhance a consumer’s wellness, and modern science has suggested its role in boosting immune health.
Biotropics Malaysia’s Physta Tongkat Ali extract is derived from the root of the plant, and is ethically sourced, according to the company.
Tongkat Ali for the suppression of SARS-CoV-2 replication
Researchers found that Physta Tongkat Ali was able to inhibit the replication of SARS-CoV-2 — the virus that causes COVID-19 — which is a significant breakthrough for the industry, as more consumers look to boost their immune health for better overall wellbeing.
The functional ingredient also had a significant positive impact on overall immunity and ‘immunity age’, which quantifies the age-related decline that naturally occurs to our immune system over time.
This study found the average immunity age of participants decreased by more than four years, which was measured through the score of immunological vigour (SIV).
Head of Performance Ingredients at Biotropics Malaysia, Nik Fahmi Mokhtar, commented: "We are thrilled to share these recent findings which affirm the efficacy of Physta Tongkat Ali. Although this ingredient has traditionally treated fevers for years, this new study proves that it can support a healthy immune system. It's important for us to build on these areas so we can prove the multi-faceted benefits of Physta."
[Photo credit: Biotropics Malaysia]
Reference
1 Sasikala., et. al., 2024. Antiviral Activity Of Physta®, Standardised Water Extract Of Eurycoma Longifolia Against Sars-Cov-2: An In Vitro Study. Malaysian Journal of Pharmaceutical Sciences Vol. 22, No. 1, 77–86. http://web.usm.my/mjps//mjps22012024/mjps22012024_5.pdf
